Analysis of the Predictive Value of EZH2 Expression Level on the Clinical Efficacy and Long-term Prognosis of Patients with Primary Gastrointestinal Diffuse Large B-cell Lymphoma.
10.19746/j.cnki.issn.1009-2137.2021.03.012
- Author:
Jian-Yang LIN
1
;
Yan-Bin ZHENG
1
;
Hong-Ming HE
2
;
Jie-Song WANG
1
;
Yu YANG
1
;
Dao-Guang CHEN
1
;
Si-Ping ZOU
1
;
Chang WANG
1
Author Information
1. Department of Lymphoma and Head and Neck Cancer, The Affiliated Tumor Hospital of Fujian Medical University, Fuzhou 350014, Fujian Province, China.
2. Department of Lymphoma and Head and Neck Cancer, The Affiliated Tumor Hospital of Fujian Medical University, Fuzhou 350014, Fujian Province, China,E-mail: 811481521@qq.com.
- Publication Type:Journal Article
- MeSH:
Enhancer of Zeste Homolog 2 Protein;
Humans;
Immunohistochemistry;
Lymphoma, Large B-Cell, Diffuse;
Prognosis;
Remission Induction;
Retrospective Studies;
Treatment Outcome
- From:
Journal of Experimental Hematology
2021;29(3):725-730
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the predictive value of methyltransferase EZH2 expression level on the clinical efficacy and long-term prognosis of patients with primary gastrointestinal diffuse large B-cell lymphoma (PGI-DLBCL).
METHODS:161 patients with newly treated PGI-DLBCL in our hospital from August 2013 to July 2019 were selected. The expression level of EZH2 protein was detected by immunohistochemistry, and the short-term efficacy and long-term survival differences of patients with different levels of EZH2 were compared. The predictive values of EZH2 expression level on the short-term efficacy and long-term prognosis of PGI-DLBCL patients were analyzed by Log-rank test and COX risk proportional regression model. Chi-square test and Logistic regression analysis were used to analyze the influencing factors of EZH2 expression level.
RESULTS:The complete response (CR) and overal response(OR) rates of those with high EZH2 expression were significantly lower than those with low EZH2 expression (P<0.001). The median OS and PFS of EZH2 high-level and low-level expression group was 37, 31 months and 49, 42 months, respectively. The cumulative OS and PFS rates of the high-level expression group were significantly lower than those of the low-level expression group, and the differences were statistically significant (P<0.05). The high expression levels of H3K27me3, EZH2, BCL-2, BCL-6, c-MYC were closely related to the shortening of OS and PFS, while the high expression level of Ki-67 was closely related to the shortening of OS (P<0.05), of which the high expression levels of H3K27me3, EZH2, BCL-2, and BCL-6 were independent risk factors for shortening of OS and PFS. The expression level of EZH2 was positively correlated with the expression level of H3K27me3, BCL-6, c-MYC and Ki-67 (r=0.741, r=0.837, r=0.809, r=0.772), and the high expression levels of H3K27me3, BCL-6 and Ki-67 were independent factors influencing the high expression of EZH2.
CONCLUSION:In patients with PGI-DLBCL, the high expression of EZH2 significantly reduces the short-term CR and OR rates, which is an independent risk factor for the shortening of long-term OS and PFS rates, and it is independently related to the high expression of H3K27me3 and BCL6.
